Drugs / Ro-Peg-Interferon α2b
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03831776 | Mar 2019 → Dec 2024 | chronic myeloid leukemia | St. Olavs Hospital | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ro-Peg-Interferon α2b | “Ro-Peg-Interferon α2b will be supplied by AOP Orphan to be administered by subcutaneous injections from prefilled injection pens.” NCT03831776 ↗ |
| Route | Subcutaneous | “administered by subcutaneous injections” NCT03831776 ↗ |